Literature DB >> 20308166

A study of patient satisfaction following endothermal ablation for varicose veins.

Ajay Gandhi1, Farid Froghi, Amanda C Shepherd, Joseph Shalhoub, Chung S Lim, Manjit S Gohel, Alun H Davies.   

Abstract

OBJECTIVE: To evaluate patient satisfaction following endothermal ablation for varicose veins (VVs).
METHODS: A 12-question survey was sent to consecutive patients treated with endothermal ablation--questions related to preprocedure symptoms, recurrence, further treatments, and patient satisfaction.
RESULTS: Questionnaires sent a median 12 (range 6-22) months postintervention were returned by 177 (60.0%) of 295 patients; 63 (35.6%) of 177 received treatment for recurrent VVs. Preintervention symptoms included aching (141 [79.7%] of 177), swelling (86 [48.6%] of 177), and heaviness (72 [40.7%] of 177). Improvements in preoperative symptoms were reported by 82.5% (146 of 177). Postintervention recurrence was reported by 87 (49.4%) of 177; 61 (70.1%) of 87 reported a few recurrent varicosities only. Further treatment was required by 11 (6.2%) of 177; 79 (44.6%) of 177 of patients reported no complications. The majority (151 [85.8%] of 176) were satisfied with their treatment. In all, 16 (25.4%) of 62 of patients treated for recurrent VVs were dissatisfied versus 9 (7.9%) of 114 of those with primary VVs (P = .0026).
CONCLUSIONS: The majority of patients are satisfied with results following endothermal ablation. Dissatisfaction may be more likely following treatment for recurrent VVs.

Entities:  

Mesh:

Year:  2010        PMID: 20308166     DOI: 10.1177/1538574410363834

Source DB:  PubMed          Journal:  Vasc Endovascular Surg        ISSN: 1538-5744            Impact factor:   1.089


  2 in total

1.  [Endovenous ablation of saphenous vein varicosis].

Authors:  Sanja Schuller-Petrovic
Journal:  Wien Med Wochenschr       Date:  2016-06-13

Review 2.  Is radiofrequency ablation of varicose veins a valuable option? A systematic review of the literature with a cost analysis.

Authors:  Thomas G Poder; Jean-François Fisette; Suzanne K Bédard; Marc-Antoine Despatis
Journal:  Can J Surg       Date:  2018-04       Impact factor: 2.089

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.